Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02000830
Previous Study | Return to List | Next Study

Follow up Study of Patients Having Participated in Clinical Trial 64,185-204 (JASMINE_205)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02000830
Recruitment Status : Completed
First Posted : December 4, 2013
Last Update Posted : March 17, 2020
Sponsor:
Information provided by (Responsible Party):
Mallinckrodt ( InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company )

Brief Summary:
The objectives of this follow up study are to evaluate the long-term effects of stannsoporfin (Stanate) on the health, growth, and development of patients who received a single dose of stannsoporfin with PT used to treat hyperbilirubinemia compared with patients in the control (placebo plus PT) group in clinical trial 64,185-204.

Condition or disease Intervention/treatment
Hyperbilirubinemia, Neonatal Drug: Stannsoporfin Drug: Placebo

Detailed Description:

Outcomes will be based on the following variables:

Reported AEs and SAEs Hearing assessments Developmental assessments

Layout table for study information
Study Type : Observational
Actual Enrollment : 68 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Four-Year Blinded Outcomes Follow-up Study of Patients Who Received Stannsoporfin or Placebo in Clinical Trial 64,185-204
Actual Study Start Date : October 17, 2013
Actual Primary Completion Date : February 28, 2020
Actual Study Completion Date : February 28, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Jaundice

Group/Cohort Intervention/treatment
Placebo
Participants received placebo during the earlier study
Drug: Placebo
Matching placebo administered by IM injection
Other Name: Matching Placebo

Stannsoporfin 3.0 mg/kg
Participants received Stannsoporfin 3.0 mg/kg during the earlier study
Drug: Stannsoporfin
Stannsoporfin administered by intramuscular (IM) injection
Other Name: Experimental product

Stannsoporfin 4.5 mg/kg
Participants received Stannsoporfin 4.5 mg/kg during the earlier study
Drug: Stannsoporfin
Stannsoporfin administered by intramuscular (IM) injection
Other Name: Experimental product




Primary Outcome Measures :
  1. Reported adverse events (AEs) [ Time Frame: 48-52 month ]

Secondary Outcome Measures :
  1. Hearing assessments [ Time Frame: 48 - 52 month ]
    Conventional audiometry will be performed by a qualified specialist. Any findings from a failed conventional audiology examination will be recorded

  2. Developmental assessments [ Time Frame: 48 - 52 month ]
    The Mullen Scales of Early Learning examination has been selected for its standardized measurement of developmental skills in multiple domains (gross motor, visual reception, fine motor, expressive language, and receptive language). Testing will be done at visits 1 and 2 by a healthcare individual trained to administer the test. The Mullen raw scores, T-scores, and age equivalents will be recorded.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 52 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who received a single dose of trial medication in clinical trial 64,185-204.
Criteria

Inclusion Criteria:

  • Patients who received IMP (stannsoporfin or placebo) in clinical trial 64,185-204
  • Parents or guardians have given written informed consent to participate

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02000830


Sponsors and Collaborators
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Investigators
Layout table for investigator information
Study Chair: Global Clinical Leader, MD InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Layout table for additonal information
Responsible Party: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
ClinicalTrials.gov Identifier: NCT02000830    
Other Study ID Numbers: 64,185-205
First Posted: December 4, 2013    Key Record Dates
Last Update Posted: March 17, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Mallinckrodt ( InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company ):
stannsoporfin
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperbilirubinemia, Neonatal
Hyperbilirubinemia
Pathologic Processes
Infant, Newborn, Diseases
Tin mesoporphyrin
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action